Can a Single Pill Replace Doublet Chemotherapy in First-Line Therapy of Advanced Non–Small Cell Lung Cancer?

Abstract

Giaccone et al. are to be congratulated for conducting a trial of the oral agent erlotinib in previously untreated patients with non–small cell lung cancer (NSCLC; ref. [1][1]). According to current American Society of Clinical Oncology guidelines, the standard therapy for these patients is a